MetroGel Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed MetroGel (metronidazole topical gel 1%) for rosacea are increasingly reporting difficulty filling their prescriptions at local pharmacies. While there is no formal FDA or ASHP drug shortage for metronidazole topical gel as of 2026, a convergence of market forces has created real access barriers that are affecting patient care and adherence.

This guide summarizes the current landscape and offers practical recommendations for prescribers managing patients on MetroGel or considering it for rosacea treatment.

Current Availability Status: No Official Shortage, But Real Access Gaps

As of 2026, metronidazole topical gel is not on any official shortage list. The active pharmaceutical ingredient (API) — metronidazole — is manufactured by multiple suppliers globally and is not at supply chain risk. However, prescribers should be aware of the following practical access issues:

Brand-name MetroGel: Rarely stocked at most chain pharmacies. Pharmacies have largely transitioned to generics. Patients requesting brand-name MetroGel will often need to go to an independent pharmacy or mail-order.

1% strength: Not universally stocked. The 1% once-daily formulation is preferred by many providers, but many pharmacies carry only the 0.75% twice-daily formulation. This mismatch causes significant patient confusion and non-adherence.

Insurance formulary restrictions: Medicare Part D typically does not cover brand-name MetroGel. Commercial plans vary. Generic metronidazole is generally covered at Tier 1–2.

Clinical Considerations: 1% vs. 0.75% Formulations

Both the 0.75% and 1% formulations of metronidazole topical gel are FDA-approved for inflammatory lesions of rosacea, but they are not interchangeable without a prescribing change:

Metronidazole 0.75% gel: Applied twice daily (morning and evening); generic widely available; cost-effective.

Metronidazole 1% gel: Applied once daily; higher concentration; preferred for adherence; not universally stocked.

If your patient is being prescribed the 1% formulation primarily for adherence reasons (once-daily vs. twice-daily dosing), and it's unavailable locally, consider whether the 0.75% twice-daily regimen is clinically appropriate and whether the patient can realistically comply with twice-daily application.

Evidence-Based Alternatives to MetroGel for Rosacea

When MetroGel is unavailable or not tolerated, the following are FDA-approved alternatives with strong evidence bases:

Ivermectin 1% cream (Soolantra): Multiple RCTs demonstrate superior efficacy to metronidazole 0.75% cream for papulopustular rosacea, with better tolerability profile. Once-daily application. Brand-only; high cost without insurance, but patient access programs may be available through Galderma.

Azelaic acid 15% gel (Finacea) or 20% cream: FDA-approved; comparable efficacy to metronidazole in many trials; generic available. The 20% formulation showed 74.7% reduction in inflammatory lesions. Good first-line alternative, especially if cost is a concern.

Low-dose doxycycline (Oracea 40 mg or sub-antimicrobial doxycycline): FDA-approved for rosacea via anti-inflammatory mechanism. Particularly appropriate for moderate-to-severe papulopustular rosacea or when topical options have failed. Generic doxycycline at sub-antimicrobial doses is a cost-effective option.

Minocycline topical foam 1.5% (Zilxi): FDA-approved in 2020; once-daily topical; efficacious in phase 3 trials. Brand-only; access can be challenging. May be an option for patients who prefer topical but need an alternative to metronidazole.

Prescribing Tips to Minimize Patient Frustration

Several prescribing adjustments can help reduce the likelihood of patients hitting access barriers:

Write prescriptions for "metronidazole topical gel" (generic) rather than "MetroGel" by brand, unless there is a specific clinical reason for the brand.

Consider writing the prescription to allow either 0.75% or 1% strength so the pharmacist can dispense whichever is in stock (with appropriate dosing instructions).

For patients who frequently struggle to fill specialty skin medications, direct them to medfinder, which can identify which pharmacies near them have the medication in stock.

Verify formulary coverage at the time of prescribing — particularly for Medicare patients, who typically cannot use brand-name MetroGel through their Part D plan.

Drug Safety Considerations When Transitioning

When switching patients from MetroGel to an alternative, keep in mind:

Metronidazole topical should be avoided near the eyes (can cause tearing/irritation). Counsel patients on proper application technique before switching them to a product with different formulation characteristics.

Both metronidazole and azelaic acid are considered acceptable during pregnancy when clearly needed, though oral alternatives (including doxycycline) should be avoided in pregnancy.

Peripheral neuropathy has been reported with post-approval topical metronidazole use (uncommon). If patients report numbness or tingling in extremities, reevaluate therapy.

For providers who want to help their patients navigate medication access more broadly, medfinder for providers is a resource that helps identify pharmacies with medications in stock so you can point patients in the right direction at the point of prescribing.